These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 39134188)

  • 41. More than Toxins-Current Prospects in Designing the Next Generation of Antibody Drug Conjugates.
    Schwach J; Abdellatif M; Stengl A
    Front Biosci (Landmark Ed); 2022 Aug; 27(8):240. PubMed ID: 36042167
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Design and Evaluation of Phosphonamidate-Linked Exatecan Constructs for Highly Loaded, Stable, and Efficacious Antibody-Drug Conjugates.
    Schmitt S; Machui P; Mai I; Herterich S; Wunder S; Cyprys P; Gerlach M; Ochtrop P; Hackenberger CPR; Schumacher D; Helma J; Vogl AM; Kasper MA
    Mol Cancer Ther; 2024 Feb; 23(2):199-211. PubMed ID: 37828728
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Cryptophycin-55/52 based antibody-drug conjugates: Synthesis, efficacy, and mode of action studies.
    Lai Q; Wu M; Wang R; Lai W; Tao Y; Lu Y; Wang Y; Yu L; Zhang R; Peng Y; Jiang X; Fu Y; Wang X; Zhang Z; Guo C; Liao W; Zhang Y; Kang T; Chen H; Yao Y; Gou L; Yang J
    Eur J Med Chem; 2020 Aug; 199():112364. PubMed ID: 32402935
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Benefits and challenges of antibody drug conjugates as novel form of chemotherapy.
    Fatima SW; Khare SK
    J Control Release; 2022 Jan; 341():555-565. PubMed ID: 34906604
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Divinylsulfonamides enable the construction of homogeneous antibody-drug conjugates.
    Huang R; Sheng Y; Wei D; Lu W; Xu Z; Chen H; Jiang B
    Bioorg Med Chem; 2020 Dec; 28(23):115793. PubMed ID: 33039798
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Antibody-Drug Conjugates: A promising breakthrough in cancer therapy.
    Parit S; Manchare A; Gholap AD; Mundhe P; Hatvate N; Rojekar S; Patravale V
    Int J Pharm; 2024 Jun; 659():124211. PubMed ID: 38750981
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Novel antibody-drug conjugates based on DXd-ADC technology.
    Chen R; Ren Z; Bai L; Hu X; Chen Y; Ye Q; Hu Y; Shi J
    Bioorg Chem; 2024 Oct; 151():107697. PubMed ID: 39121594
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Recent Chemical Approaches for Site-Specific Conjugation of Native Antibodies: Technologies toward Next-Generation Antibody-Drug Conjugates.
    Yamada K; Ito Y
    Chembiochem; 2019 Nov; 20(21):2729-2737. PubMed ID: 30973187
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Linkers Having a Crucial Role in Antibody-Drug Conjugates.
    Lu J; Jiang F; Lu A; Zhang G
    Int J Mol Sci; 2016 Apr; 17(4):561. PubMed ID: 27089329
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Phenyldivinylsulfonamides for the construction of antibody-drug conjugates with controlled four payloads.
    Wei D; Jiang Y; Mao Y; Xu Z; Chen J; Gao X; Li J; Jiang B; Chen H
    Bioorg Chem; 2023 May; 134():106463. PubMed ID: 36924655
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Antibody-Drug Conjugates for the Treatment of Hematological Malignancies: A Comprehensive Review.
    Rossi C; Chrétien ML; Casasnovas RO
    Target Oncol; 2018 Jun; 13(3):287-308. PubMed ID: 29556925
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Antibody-drug conjugates: Promising and efficient tools for targeted cancer therapy.
    Nasiri H; Valedkarimi Z; Aghebati-Maleki L; Majidi J
    J Cell Physiol; 2018 Sep; 233(9):6441-6457. PubMed ID: 29319167
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The Evolution of Antibody-Drug Conjugates: Toward Accurate DAR and Multi-specificity.
    Dong W; Wang W; Cao C
    ChemMedChem; 2024 Sep; 19(17):e202400109. PubMed ID: 38758596
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Modulating Antibody-Drug Conjugate Payload Metabolism by Conjugation Site and Linker Modification.
    Su D; Kozak KR; Sadowsky J; Yu SF; Fourie-O'Donohue A; Nelson C; Vandlen R; Ohri R; Liu L; Ng C; He J; Davis H; Lau J; Del Rosario G; Cosino E; Cruz-Chuh JD; Ma Y; Zhang D; Darwish M; Cai W; Chen C; Zhou H; Lu J; Liu Y; Kaur S; Xu K; Pillow TH
    Bioconjug Chem; 2018 Apr; 29(4):1155-1167. PubMed ID: 29481745
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The New Frontier: Merging Molecular Glue Degrader and Antibody-Drug Conjugate Modalities To Overcome Strategic Challenges.
    Poudel YB; Thakore RR; Chekler EP
    J Med Chem; 2024 Sep; 67(18):15996-16001. PubMed ID: 39231796
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Development and Properties of Valine-Alanine based Antibody-Drug Conjugates with Monomethyl Auristatin E as the Potent Payload.
    Wang Y; Fan S; Zhong W; Zhou X; Li S
    Int J Mol Sci; 2017 Aug; 18(9):. PubMed ID: 28841157
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Use of pyrrolobenzodiazepines and related covalent-binding DNA-interactive molecules as ADC payloads: Is mechanism related to systemic toxicity?
    Jackson PJM; Kay S; Pysz I; Thurston DE
    Drug Discov Today Technol; 2018 Dec; 30():71-83. PubMed ID: 30553523
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Antibody-drug conjugates: Recent advances in payloads.
    Wang Z; Li H; Gou L; Li W; Wang Y
    Acta Pharm Sin B; 2023 Oct; 13(10):4025-4059. PubMed ID: 37799390
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Advances with antibody-drug conjugates in breast cancer treatment.
    Abdus Subhan M; Torchilin VP
    Eur J Pharm Biopharm; 2021 Dec; 169():241-255. PubMed ID: 34748933
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Development and evaluation of β-galactosidase-sensitive antibody-drug conjugates.
    Kolodych S; Michel C; Delacroix S; Koniev O; Ehkirch A; Eberova J; Cianférani S; Renoux B; Krezel W; Poinot P; Muller CD; Papot S; Wagner A
    Eur J Med Chem; 2017 Dec; 142():376-382. PubMed ID: 28818506
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.